Tanja Hochstrasser

Dr. Tanja Hochstrasser

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Brain Research
Verified
Journal Article
Closed access
KHKatharina Marie Höflich
Katharina Marie Höflich
CBCordian Beyer
Cordian Beyer
TCTim Clarner
Tim Clarner
CSChristoph Schmitz
Christoph Schmitz
SNStella Nyamoya
Stella Nyamoya
THTanja Hochstrasser
Tanja Hochstrasser

25 February 2017 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
THTanja Hochstrasser
Tanja Hochstrasser
GEGianna Lisa Exner
Gianna Lisa Exner
SNStella Nyamoya
Stella Nyamoya
CSChristoph Schmitz
Christoph Schmitz
MKMarkus Kipp
Markus Kipp

21 September 2018 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
SRSebastian Rühling
Sebastian Rühling
FKFranziska Kramer
Franziska Kramer
SSSelina Schmutz
Selina Schmutz
SASandra Amor
Sandra Amor
ZJZhan Jiangshan
Zhan Jiangshan
THTanja Hochstrasser
Tanja Hochstrasser

3 September 2019 in Cells
Verified
Journal Article
Open access
PDF file
THTanja Hochstrasser
Tanja Hochstrasser
SRSebastian Rühling
Sebastian Rühling
KHKerstin Hecher
Kerstin Hecher
KFKai Fabisch
Kai Fabisch
UCUta Chrzanowski
Uta Chrzanowski
Markus KippMarkus Kipp
Markus Kipp
Brain volume measurement is one of the most frequently used biomarkers to establish neuroprotective effects during pre-clinical multiple sclerosis (MS) studies. Furthermore, whole-brain atrophy estimates in MS correlate more robustly with clinical disability than traditional, lesion-based metrics. However, the underlying mechanisms leading to brain atrophy are poorly understood, partly due to the lack of appropriate animal models to study this aspect of the disease. The purpose of this study was to assess brain volumes and neuro-axonal degeneration after acute and chronic cuprizone-induced demyelination. C57BL/6 male mice were intoxicated with cuprizone for up to 12 weeks. Brain volume, as well as total numbers and densities of neurons, were determined using design-based stereology. After five weeks of cuprizone intoxication, despite severe demyelination, brain volumes were not altered at this time point. After 12 weeks of cuprizone intoxication, a significant volume reduction was found in the corpus callosum and diverse subcortical areas, particularly the internal capsule and the thalamus. Thalamic volume loss was accompanied by glucose hypermetabolism, analyzed by [18F]-fluoro-2-deoxy-d-glucose (18F-FDG) positron-emission tomography. This study demonstrates region-specific brain atrophy of different subcortical brain regions after chronic cuprizone-induced demyelination. The chronic cuprizone demyelination model in male mice is, thus, a useful tool to study the underlying mechanisms of subcortical brain atrophy and to investigate the effectiveness of therapeutic interventions.

1 October 2020 in Brain Research
Verified
Journal Article
Closed access
CRChristin Reinbach
Christin Reinbach
MSMaria-Sophia Stadler
Maria-Sophia Stadler
NPNicolas Pröbstl
Nicolas Pröbstl
UCUta Chrzanowski
Uta Chrzanowski
CSChristoph Schmitz
Christoph Schmitz
THTanja Hochstrasser
Tanja Hochstrasser

13 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
THTanja Hochstrasser
Tanja Hochstrasser
.K.Leon Kaub
.Leon Kaub
LMLeonard Maier
Leonard Maier
NANicholas Baker Angstman
Nicholas Baker Angstman
TKTomonori Kenmoku
Tomonori Kenmoku
CSChristoph Schmitz
Christoph Schmitz
Background/Objectives: Cerebral palsy (CP) is a leading cause of motor disability in children and is commonly associated with spasticity. Treatment with radial extracorporeal shock waves (rESWs) is an established non-invasive therapy for spasticity, although its underlying mechanisms remain poorly understood. Caenorhabditis elegans (C. elegans) represents a powerful model for neuromuscular research due to its fully mapped nervous system, conserved cholinergic pathways and suitability for high-throughput behavioral analysis. This study aimed to test whether rESWs modulate cholinergic signaling at the neuromuscular junction (NMJ) in C. elegans. Methods: Wild-type and acr-16 mutant C. elegans were exposed in liquid to varying doses of rESWs, nicotine and carbachol in different combinations. Locomotor behavior was recorded using high-resolution video tracking, and parameters including peristaltic speed, body wavelength, reversals and omega bends were quantified. Results: Exposure to rESWs transiently altered locomotion, most notably by reducing forward speed and increasing the frequency of reversals. However, rESWs did not consistently modify behavioral responses to nicotine or carbachol, and these effects were not clearly dependent on NMJ-associated nicotinic receptors. Conclusions: Exploring C. elegans as a model for rESW effects on spasticity proved informative but also revealed important limitations. Results indicate that rESWs act on the nervous system more broadly, extending beyond neuromuscular structures. This contrasts with the clinical situation, where rESWs primarily target muscles and connective tissues. While this precludes C. elegans as a direct model for CP-related spasticity, the observation that rESWs influence nervous-system function at a systemic level points to potential therapeutic avenues for neurological diseases.